Lucid Diagnostics to Present at 22nd Annual Needham Virtual Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention diagnostics company and a subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), announced that its leadership team, including Dr. Lishan Aklog and Dennis McGrath, will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023, at 11:00 AM ET.
Lucid's focus is on patients with gastroesophageal reflux disease (GERD), at risk of esophageal cancer. Their EsoGuard® Esophageal DNA Test, a non-invasive diagnostic tool, is designed for early detection of esophageal precancer. This test is significant as it is the first commercially available screening tool targeting at-risk GERD patients.
For more details, visit luciddx.com or pavmed.com.
Details
News Market Reaction – PAVM
The recorded move for PAVM in the trading session of this news was +18.25%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, April 17, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Dr. Lishan Aklog, Chairman and Chief Executive Officer; and Dennis McGrath, Chief Financial Officer will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 11:00 AM ET.
Institutional investors interested in meeting with management during the conference may reach out to their Needham representative.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.
For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-present-at-22nd-annual-needham-virtual-healthcare-conference-301799619.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.